Clinical trial for Multiple Myeloma
Official title A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
ClinicalTrials.gov ID: NCT06953960
What this study is testing
What is Surzetoclax?
An investigational oral medicine being studied as a potential treatment for relapsed/refractory multiple myeloma.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether surzetoclax is safe and changes disease activity in adults with relapsed/refractory multiple myeloma.
- Who it's for
- You may be able to join if you are an adult with relapsed or refractory multiple myeloma.
- What's involved
- You would take oral surzetoclax tablets, sometimes with injections or other oral medicines. You will have regular doctor visits, blood tests, and check‑ups for side effects.
- Time commitment
- The study lasts about 4.5 years with regular visits for assessments and blood tests.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Documented diagnosis of multiple myeloma (MM) based on standard international myeloma working group (IMWG) diagnostic criteria.
- Serum M-protein \>= 0.5 g/dL (\>= 5g/L); OR
- Urine M-protein \>= 200 mg/24 hours; OR
- For participants without measurable serum and urine M-protein: Serum free light chain (sFLC) \>= 10 mg/dL (100 mg/L), provided sFLC ratio is abnormal.
- B-cell lymphoma (BCL)-2 inhibitor treatment naïve.
You likely can't join if
- Major surgery within 4 weeks of study treatment or planned during study participation.
- Recent infection requiring systemic treatment that was completed \<= 14 days before first dose of study treatment and/or uncontrolled active systemic...
See the full eligibility criteria
- Documented diagnosis of multiple myeloma (MM) based on standard international myeloma working group (IMWG) diagnostic criteria.
- Serum M-protein \>= 0.5 g/dL (\>= 5g/L); OR
- Urine M-protein \>= 200 mg/24 hours; OR
- For participants without measurable serum and urine M-protein: Serum free light chain (sFLC) \>= 10 mg/dL (100 mg/L), provided sFLC ratio is abnormal.
- B-cell lymphoma (BCL)-2 inhibitor treatment naïve.
- t(11;14) positive status and/or BCL2 high status.
- Must have confirmed diagnosis of relapsed or refractory (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen, based on the investigator's...
- Major surgery within 4 weeks of study treatment or planned during study participation.
- Recent infection requiring systemic treatment that was completed \<= 14 days before first dose of study treatment and/or uncontrolled active systemic infection.
The study team makes the final eligibility decision.
Where it is enrolling
- Los Angeles, California, United States
- New Haven, Connecticut, United States
- Boston, Massachusetts, United States
- Ann Arbor, Michigan, United States
- New York, New York, United States
- Charlotte, North Carolina, United States
- Hillsborough, North Carolina, United States
- Winston-Salem, North Carolina, United States
- Portland, Oregon, United States
- Dallas, Texas, United States
- Salt Lake City, Utah, United States
- Tacoma, Washington, United States
- Liverpool, New South Wales, Australia
- Waratah, New South Wales, Australia
- Fitzroy, Victoria, Australia
- Richmond, Victoria, Australia
- Ghent, Oost-Vlaanderen, Belgium
- Leuven, Vlaams-Brabant, Belgium
- Liège, Belgium
- Montpellier, Herault, France
+ 30 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Los Angeles, California, United States; New Haven, Connecticut, United States; Boston, Massachusetts, United States; Ann Arbor, Michigan, United States; New York, New York, United States; Charlotte, North Carolina, United States and 44 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.